Once daily mesalazine more than doubles compliance
The new once daily oral formulation of the ulcerative colitis drug mesalazine is safe and effective and could increase compliance rates up over 90%, say Australian researchers.
Although older mesalazine formulations – six tablets a day in divided doses, suppositories or enemas – have shown to maintain remission in UC patients, compliance can be as low as 40%.
The new formulation, Mezavent XL, has been available in the UK since October and allows once daily oral dosing. In this new study 174 UC patients were randomised to receive either once or twice daily treatment.
By six months 64% of those using the once daily dose were in remission compared to 68% of those taking it twice daily. Compliance overall was 95% on average.
Gut published online 13 February.